Chimeric Mouse Model with
Highly Humanized Liver
KMT Hepatech Phoenix Bio Logo
KMT Hepatech is a preclinical development contractor for the NIH / NIAID
pxb-mouse with human hepatocytes
Stable human hepatocyte
engraftment of up to
95 per cent
previous arrow
next arrow
Slider

KMT Hepatech, Inc. is a part of PhoenixBio group since December 1, 2017

KMT Hepatech provides efficient and cost-effective in vivo research services utilizing platform technology of small animal model, the PXB-Mouse®.

The PXB-Mouse® is a chimeric mouse model with humanized liver with stable human hepatocytes engraftment of over 70 per cent.

In addition to in vivo services, KMT Hepatech will expand operations and start production of PXB-Cells® – hepatocytes isolated from a PXB-Mouse®liver.

Due to the expanding interest in the humanized liver mouse model across a wide range of drug development fields, the company now offers services in the following areas:

  • Infectious diseases, such as Hepatitis C, Hepatitis B and Malaria
  • Safety toxicity: early assessment of potential hepatotoxicity in in vivosettings prior to first-in-human studies
  • Characterization of human-type drug and lipoprotein metabolism in in vivo settings prior to first-in-human studies

KMT Hepatech, Inc. owns an international patent portfolio that includes coverage of the uPA chimeric mouse model of HCV infection and on the uPA chimeric mouse for all potential applications including HBV, malaria and studies of toxicity, drug and lipoprotein metabolism.

The PXB-Mouse® and PXB-Cells® are your essential tools for therapeutics and vaccine development.

News and Events

Expansion of Staff and Operations in Edmonton

KMT Hepatech, Inc. (“KMT”), a part of PhoenixBio group, announced plans to expand staff and operations by providing services with PXB-Mouse® and starting the production of the PXB-Cells® – hepatocytes isolated from cDNA-uPA/SCID mice with…
Close Menu